Related Experiment Video
Updated: Jun 20, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Acquired factor V inhibitor in a critically ill patient
1Department of Anaesthesia, Stoke Mandeville Hospital, Buckinghamshire, UK. carljmorris@googlemail.com
Acquired inhibitor of factor V is a rare bleeding disorder. Early recognition of this condition is crucial for managing patients with unexplained prolonged clotting times.
Area of Science:
- Hematology
- Internal Medicine
Background:
- Acquired inhibitor of factor V (FVIII) is a rare autoimmune condition.
- It can lead to severe bleeding complications.
Observation:
- A case report from an intensive care unit setting is presented.
- The patient exhibited less common causes of elevated prothrombin and activated partial thromboplastin times.
Findings:
- The study highlights the variable clinical presentations of acquired inhibitor of factor V.
- Variable presentation can complicate diagnosis and management.
Implications:
- Awareness of the diverse manifestations of acquired inhibitor of factor V is essential for clinicians.
- Prompt diagnosis and appropriate management can improve patient outcomes in critical care settings.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Acute Respiratory Failure-IV
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pulmonary Embolism III: Nursing Management
